More Weight Loss Solutions

New Study Reveals Zepbound’s Impact on Blood Pressure and Weight Loss – Medriva

Feb 6th, 2024

In the contemporary world, the fight against obesity goes hand in hand with the battle against high blood pressure. Both conditions share a stubbornly intertwined relationship, whereby obesity often leads to high blood pressure, which in turn contributes to heart disease. As such, any breakthrough in the treatment of one can have a profound impact on the other. A recent study published in the American Heart Associations journal Hypertension has opened up a new front in this ongoing battle, revealing that the weight loss drug Zepbound (generic name tirzepatide) can significantly reduce blood pressure in individuals with obesity.

The study involved 500 participants being treated with various dosages of Zepbound. The researchers utilized 24-hour blood pressure monitoring devices to measure systolic blood pressure. The results were encouraging: a decrease in systolic blood pressure of 7 to 10 points was observed, depending on the dosage of Zepbound administered. This reduction is comparable to, or even better than, traditional drugs for treating high blood pressure.

Zepbound, also sold under the brand name Mounjaro, is a product by Eli Lilly. While it was initially developed to treat Type 2 diabetes and obesity, its potential to lower blood pressure emerged as a significant added benefit during the course of the study. However, researchers were unable to distinguish whether the reduction in blood pressure was a direct effect of the drug or a result of weight loss induced by the drug.

Participants taking 10 milligram doses of Zepbound saw the greatest reductions in systolic blood pressure. This is significant, as research shows that obesity accounts for between 65% and 78% of cases of primary hypertension. A broader clinical trial published in 2022 had already found that weekly doses of tirzepatide led to weight loss in up to 22.5% of participants. The FDA approved the medication for weight loss in November 2023, following an average 18% reduction in body weight among people with overweight or obesity who took the drug for nearly a year and a half.

Zepbound works by mimicking two hormones in the body that stimulate insulin secretion and sensitivity after a person eats. The SURMOUNT 1 trial showed that tirzepatide was associated with significant reductions in systolic blood pressure, with mean reductions of 7.4 mmHg with tirzepatide 5 mg, 10.6 mmHg with tirzepatide 10 mg, and 8.0 mmHg with tirzepatide 15 mg. The trial also demonstrated weight loss effects, with mean percentage changes in weight at week 72 being 15.0% with tirzepatide 5 mg, 19.5% with tirzepatide 10 mg, and 20.9% with tirzepatide 15 mg, compared to 3.1% with placebo.

In conclusion, the discovery of Zepbounds potential to significantly reduce blood pressure in people with obesity is a major breakthrough. It not only offers a new treatment option for those struggling with obesity and high blood pressure, but also provides a foundation for further research into the synergistic treatment of these two interconnected health conditions.

Read more:
New Study Reveals Zepbound's Impact on Blood Pressure and Weight Loss - Medriva

Related Posts

Contact One Of Our Consultants Today

Your Full Name
Your Email
Your Phone Number
Select your age (30+ only)
Confirm over 30 years old  Yes
Confirm that you are a US Citizen  Yes
This is a Serious Inquiry  Yes
Select A Program
Select Your US State
captcha Please Enter Code:

Comments are closed.
Weight Loss Solutions
matomo tracker